Gilead Sciences Acquires XinThera
May 9, 2023
Gilead Sciences has acquired all outstanding shares of XinThera, a San Diego–based private biotechnology company, adding small-molecule oncology and inflammation programs (including PARP1-selective and MK2-targeting assets) to its early pipeline. Financial terms were not disclosed; XinThera was backed by investors including Foresite Capital, OrbiMed and TTM Capital.
- Buyers
- Gilead Sciences
- Targets
- XinThera
- Sellers
- Foresite Capital, OrbiMed Advisors, TTM Capital
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.